Skip to main content
editorial
. 2020 Sep 7;26(33):4889–4899. doi: 10.3748/wjg.v26.i33.4889

Table 2.

Recently identified potential inflammatory bowel disease treatments.

Treatment Biomarkers changed in desired direction Ref1 Ref2
Taraxasterol ROS, MDA, Caspase-3, Bcl-2, Bax, Nrf2, HO-1, NQO-1, GPx-3 [74] [75]
Rhodiola rosea; Salidroside IL-6, sIL-6R, IFN-gamma, IL-17A, IL-4, Th1 cells, Th17 cells, Treg cells, JAK1, JAK2, STAT3, RORgammat [76-78] [79]
VAS2870 Nox2, ROS, Epithelium barrier integrity, Cell viability [80] [81]
Pinitol Oxidative stress, ROS, TNF-alpha, IL-1beta, IL-6, NO, PGE2, iNOS, COX-2, IkappaBalpha, NF-kappaB, TREM2, Inflammation [82] [83]
TAK-242; Resatorvid TLR4, Apoptosis, IL-1beta, Inflammation [84] [85]
Troxerutin CK-mB, MDA, ROS, ATP [86] [87]
Vinpocetine MAPK, NF-kB, MMP-9, AKT, ROS, Nrf2, HO-1, NQO-1, IL-1beta, TNF-alpha [88] [89]
Poria Cocos ROS, MDA, SOD, LOX-1, Nrf2, HO-1, ERK, Oxidative stress [90] [91]
Carvacrol Nrf2, ROS, MDA, SOD, Oxidative stress [92] [93]
Saururus Chinensis NF-kB IL-6 IL-8 [94] [95]